Protagonist Q2 net loss $30.8M; rusfertide gets FDA Breakthrough Therapy; Phase 3 on track

Protagonist Therapeutics, Inc

2022-Q2 EPS reported -$1.23 revenue$8,454,000

Net loss $30.8M ($0.69/share) vs $19.4M ($0.59) in Q2 2020; cash $380.4M expected to fund through 2024.
Rusfertide granted FDA Breakthrough Therapy for polycythemia vera; Phase 3 start expected early 2022.
Janssen collaboration amended: Janssen leads worldwide development; Protagonist eligible for ~$900M milestones plus $80M received.
Completed public offering of 3.5M shares at $37.75, raising ~$132.2M gross proceeds.
PN-943 Phase 2 data for ulcerative colitis anticipated in Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.